Is EyePoint Poised To Open New Eyes In Retinal Disease Care?

EyePoint Pharmaceuticals Inc. (EYPT) has stepped into the spotlight after reaching a new 52-week high on Thursday, December 4, 2025. The company's late-stage clinical programs and strengthened financial position have placed it firmly in focus as one to watch in the ophthalmology space.

Strong Move on the Screen

Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe Now
Already subscribed? Sign in

by RTTNews Staff Writer

For comments and feedback: editorial@rttnews.com